Drugs / ALG-125755
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05561530 | Oct 2022 → Jun 2023 | chronic hepatitis B virus infection | Aligos Therapeutics | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-06-21 | Aligos Therapeutics | Results Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023 aligos.com ↗
Specifically, subjects from cohorts 1 (50 mg, n=6) and cohort 2 (120 mg, n=6) demonstrated a sustained dose dependent reduction in HBsAg levels over 90 days. |
| 2023-06-07 | Aligos Therapeutics | Results Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023 aligos.com ↗
Single subcutaneous doses of 50 mg of ALG-125755, an siRNA designed to reduce hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (CHB), were shown to be well tolerated to date in HBeAg negative CHB subjects with a safety and PK profile supporting further evaluation of higher dose levels. |
| 2021-11-12 | Aligos Therapeutics | Results Aligos Therapeutics Presents Data for its Chronic Hepatitis B (CHB) and Nonalcoholic Steatohepatitis (NASH) Portfolio at The Liver Meeting® 2021 aligos.com ↗
Triple combinations of the siRNA ALG-125755 and STOPS ALG-010133 with the ASO ALG-020572 showed additive activity in reducing HBsAg and demonstrated a dose-dependent response with respect to the ASO. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-06-21 | Aligos Therapeutics | Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023 aligos.com ↗ |
| 2023-06-07 | Aligos Therapeutics | Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023 aligos.com ↗ |
| 2022-12-14 | Aligos Therapeutics | Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB) aligos.com ↗ |
| 2022-10-14 | Aligos Therapeutics | Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755 aligos.com ↗ |
| 2021-11-12 | Aligos Therapeutics | Aligos Therapeutics Presents Data for its Chronic Hepatitis B (CHB) and Nonalcoholic Steatohepatitis (NASH) Portfolio at The Liver Meeting® 2021 aligos.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALG-125755 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05561530 ↗ |
| Route | Subcutaneous | “Subcutaneous injections of ALG-125755” NCT05561530 ↗ |